Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Dec 1;48(12):2012-2020.
doi: 10.2337/dc24-2841.

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Collaborators, Affiliations
Observational Study

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

John B Buse et al. Diabetes Care. .

Abstract

Objective: Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control.

Research design and methods: Individuals with type 2 diabetes and HbA1c 7.5%-11.5% (58-102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure-lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed.

Results: Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure-lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium-glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure-lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03).

Conclusions: Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Multiple logistic regression model for hypercortisolism vs. no hypercortisolism. Error bars: 95% CIs.
Figure 2
Figure 2
Results of adrenal CT scans in participants with hypercortisolism. Abdominal CT scan results were available in 219 of 252 (86.9%) participants. Reasons for not completing the CT scan included withdrawal of consent (n = 13), lost to follow-up (n = 6), physician decision (n = 2), and other (n = 12).

Comment in

References

    1. National Diabetes Statistics Report . Centers for Disease Control and Prevention, 2024. Accessed 12 June 2024. Available from https://www.cdc.gov/diabetes/php/data-research/index.html
    1. Avramidis I, Apsemidou A, Lalia AZ, et al. Lessons from a diabetes clinic: achieving glycemic goals and clinical use of antidiabetic agents in patients with type 2 diabetes. Clin Diabetes 2020;38:248–255 - PMC - PubMed
    1. Caballero AE, Nordstrom BL, Liao B, et al. Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study. J Diabetes Complications 2021;35:108011. - PubMed
    1. Aresta C, Soranna D, Giovanelli L, et al. When to suspect hidden hypercortisolism in type 2 diabetes: a meta-analysis. Endocr Pract 2021;27:1216–1224 - PubMed
    1. Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int J Mol Sci 2021;22:623 - PMC - PubMed

Publication types